profit from every $100 of sales.
$0$100
Kamada
$8.09-0.49% today
+14.3% in 1 year
1-year low $6.681-year high $9.31
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $23.12 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Kamada sold, what it kept, and what it did with the cash.
Sales went from $129 million in 2022 to $180 million in 2025, with $20.2 million of profit last year.
SalesProfit
Kamada handed back 74% of the cash it generated last year.
$12M
Free cash flow 2025$16M
Bought back its own shares–
Paid as dividends$12M
Cash vs. debt$75M vs. $12M
Kamada vs. similar companies
Kamada grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Kamada | 23.1× · Fair price | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Kamada's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 129 | 143 | 161 | 180 | |
| 47 | 55 | 70 | 76 | |
| 5 | 10 | 20 | 26 | |
| 11 | 22 | 28 | 39 | |
| -2 | 8 | 14 | 20 | |
| -0.05 | 0.15 | 0.25 | 0.35 | |
| 36.1% | 38.9% | 43.5% | 42.3% | |
| 3.5% | 7.1% | 12.5% | 14.5% | |
| -1.8% | 5.8% | 9.0% | 11.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 322 | 355 | 372 | 379 |
| Cash | 34 | 56 | 78 | 75 |
| Total debt | 21 | 9 | 11 | 12 |
| Total liabilities | 146 | 111 | 113 | 110 |
| 176 | 244 | 259 | 269 | |
| 46 | 54 | 58 | 58 | |
| -0.5% | 3.0% | 4.1% | 6.8% | |
| -1.3% | 3.4% | 5.6% | 7.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 29 | 4 | 48 | 25 | |
| 4 | 6 | 11 | 10 | |
| 25 | -2 | 37 | 16 | |
| Dividends paid | – | 0 | 0 | 12 |
| – | – | – | – | |
| 1 | 1 | 1 | 1 |
Valuation
- 23.1×
- 16.0×
- –
- 1.8×
- 2.6×
- 29.9×
- 10.3×
- 3.3%
- 4.3%
- 3.0%
Profitability
- 42.3%
- 14.5%
- 11.2%
- 20.9%
- 6.8%
- 2.8%
- 7.7%
- 5.4%
- 7.9%
- 7.2%
Growth
- +11.7%
- –
- −54.1%
- –
- +6.5%
Financial health
- -1.7×
- 0.04
- 3.1%
- 30.3×
- 4.07
- 2.28
- 0.48
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 43%of 946
Top 36%of 872
Top 38%of 563
Top 48%of 868
Top 32%of 986
What analysts expect
- Average price target
- $12.00
- Range
- $11.00 – $13.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | 0.07 | 0.12 | −41.7% |
| Mar 11, 2026 | 0.06 | 0.09 | −33.3% |
| Nov 10, 2025 | 0.09 | 0.10 | −10.0% |
| Aug 13, 2025 | 0.13 | 0.09 | +44.4% |
| May 14, 2025 | 0.07 | 0.07 | +0.0% |
| Mar 5, 2025 | 0.07 | 0.05 | +40.0% |
| Nov 13, 2024 | 0.07 | 0.07 | +0.0% |
| Aug 14, 2024 | 0.08 | 0.06 | +33.3% |
3.0%of the share price, paid each year
On $1,000 invested$30a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
57.1% of its profit
Room to growStretchedMore than it earns: 73.7%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
54No pass
Benjamin Graham
57No pass
Philip Fisher
46No pass
Peter Lynch
67Pass
Joel Greenblatt
29No pass
Charlie Munger
41No pass
Terry Smith
39No pass
Questions about Kamada
Is Kamada a good stock to buy?
A solid business at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Kamada AI analysis
What does Kamada do?
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. It is in Drug Manufacturers - Specialty & Generic.
Does Kamada pay a dividend?
Yes. At today's price the dividend is 3.0% a year, about 57% of its yearly profit. In 2025 it paid out $11.5 million in dividends.
Is Kamada stock halal?
Yes. Kamada passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has Kamada stock done over the past year?
Up 14.3% over the past twelve months, to $8.09. It traded between $6.68 and $9.31 and is 13.1% below its high.
Who are Kamada's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Kamada's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.